Targeted Proteomics Reveals Quantitative Differences in Low Abundance Glycosyltransferases of Patients with Congenital Disorders of Glycosylation
R. Sakson, L. Beedgen, P. Bernhard, K. M. Alp, N. Luebbehusen, R. Roeth, B. Niesler, M. P. Mayer, C. Thiel, T. Ruppert
This study develops a targeted proteomics assay to quantify low-abundance glycosyltransferases in CDG patients, revealing specific protein level changes in ALG1 and ALG2 mutants.
bioRxiv · Sep 15, 2020Biochemistry